<?xml version="1.0" encoding="UTF-8"?>
<p>In the non‐intensive pathway there was a small but highly significant difference in favour of CTDa for Pain at 3 months with a persistent trend for benefit at 6 and 12 months (Pain lower for CTDa, 3 months: −8·88 [95% CI −13·58, −4·18], 
 <italic>P</italic> = 0·0002; 6 months: −4·82 [95% CI −9·91, 0·26], 
 <italic>P</italic> = 0·06; 12 months: −4·57 [95% CI −11·96, 2·81], 
 <italic>P</italic> = 0·22, Fig 
 <xref rid="bjh15459-fig-0002" ref-type="fig">2</xref>B). This difference was smaller than our pre‐specified MID. There were no significant differences for Fatigue, Global Health Status/Quality of Life or Physical Functioning (Fig 
 <xref rid="bjh15459-fig-0002" ref-type="fig">2</xref>B).
</p>
